Search Cancer Clinical Trials

Mass General Cancer Center offers patients access to a wide variety of clinical trials of promising new therapies. Use the search tool to find open protocols for your type of cancer.
20 results
  • Leukemia

19-422          Phase I

A Phase 1 First in Human Study of the Menin-MLL(KMT2A) Inhibitor KO-539 in Patients with Relapsed or Refractory Acute Myeloid Leukemia

  • Leukemia

23-031          Phase I

A Phase 1 Open-label, Multi-center Study of the Safety, Pharmacokinetics (PK), and Anti-tumor Activity of LYT- 200 in Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML), or with Relapsed/Refractory, High-risk Myelodysplastic Syndrome (MDS)

  • Leukemia

20-191          Phase I

A Phase 1 Study of SEA-CD70 in Myeloid Malignancies

  • Myelodysplastic Syndromes, Leukemia

21-217          Phase I

A PHASE 1, OPEN-LABEL, DOSE-FINDING STUDY OF CC-91633 (BMS-986397) IN SUBJECTS WITH RELAPSED OR REFRACTORY ACUTE MYELOID LEUKEMIA OR RELAPSED OR REFRACTORY HIGHER-RISK MYELODYSPLASTIC SYNDROMES

  • Leukemia

21-751          Phase II

A Phase 1/2 Open Label, Multicenter, Dose Escalation and Expansion Study of the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of HM43239 in Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML)

  • Leukemia

22-458          Phase I

A Phase 1b Study of JNJ-75276617 in Combination with AML Directed Therapies for Participants with Acute Myeloid Leukemia Harboring KMT2A or NPM1 Alterations

  • Leukemia

22-105          Phase I

A phase 1b, multicenter, open label platform study of select drug combinations in adult patients with lower risk (very low, low, or intermediate risk) myelodysplastic syndrome

  • Leukemia

21-113          Phase II

A Phase 2 Randomized Study Comparing Venetoclax and Azacitidine to Induction Chemotherapy for Newly Diagnosed Fit Adults with Acute Myeloid Leukemia

  • Leukemia

21-132          Phase II

A Phase 2, Open-Label, Multicenter, Rollover Study to Provide Continued Treatment for Participants With Advanced Malignancies Previously Enrolled in Studies of Parsaclisib (INCB050465)

  • Leukemia, Lymphoma, Cellular Therapy

19-087          Phase I

A Phase I Clinical Trial with CAR-37 T Cells for the Treatment of Patients with Relapsed or Refractory CD37+ Hematologic Malignancies

Showing 1 - 10 of 20 results